Canada Pension Plan Investment Board Purchases Shares of 186,330 Insulet Corporation $PODD

Canada Pension Plan Investment Board acquired a new position in shares of Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 186,330 shares of the medical instruments supplier’s stock, valued at approximately $28,369,000. Canada Pension Plan Investment Board owned 0.27% of Insulet as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Glenmede Investment Management LP lifted its holdings in shares of Insulet by 1.6% during the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after acquiring an additional 35 shares in the last quarter. Curi Capital LLC increased its holdings in Insulet by 0.8% in the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after purchasing an additional 36 shares in the last quarter. Great Lakes Advisors LLC increased its holdings in Insulet by 1.5% in the 4th quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock valued at $791,000 after purchasing an additional 40 shares in the last quarter. Camarda Financial Advisors LLC raised its position in Insulet by 0.5% in the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after purchasing an additional 40 shares during the period. Finally, Larson Financial Group LLC raised its position in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares during the period.

Analyst Ratings Changes

A number of research firms have recently issued reports on PODD. Bank of America lowered their target price on Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Royal Bank Of Canada reduced their price target on Insulet from $245.00 to $160.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Piper Sandler decreased their price target on Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. Oppenheimer downgraded shares of Insulet from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Finally, Benchmark reduced their target price on shares of Insulet from $250.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Fourteen research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Insulet has a consensus rating of “Hold” and a consensus target price of $195.40.

Insiders Place Their Bets

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were bought at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.36% of the stock is currently owned by insiders.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s latest reported quarter showed strong fundamentals: revenue rose 23.5% year over year to $801.7 million, while adjusted earnings of $1.66 per share exceeded the $1.47 analyst consensus. The company has also issued fiscal 2026 earnings guidance, with analysts projecting approximately $6.51 per share. Insulet financial and trading information
• Neutral Sentiment: Multiple law firms—including Rosen, Bragar Eagel & Squire, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, and Robbins Geller—reminded investors that August 31, 2026 is the deadline to seek lead-plaintiff status in the securities class action. The notices generally cover purchases made between February 21, 2025 and May 26, 2026, although one complaint cites a later starting date of May 21, 2025. Rosen Insulet deadline notice
• Negative Sentiment: The litigation creates an overhang because investors allege Insulet and certain officers violated federal securities laws and seek damages. The notices reference two Omnipod medical-device corrections and a decline of more than $90 per share from pre-disclosure levels, potentially increasing concerns about product quality, disclosure practices, legal costs, and reputational risk. The allegations have not been proven. Insulet investor litigation alert

Insulet Price Performance

Shares of PODD opened at $145.13 on Friday. The firm has a market cap of $10.06 billion, a price-to-earnings ratio of 27.13, a PEG ratio of 1.13 and a beta of 1.10. The stock has a 50 day moving average of $154.46 and a 200-day moving average of $181.15. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. Insulet Corporation has a 52 week low of $126.40 and a 52 week high of $354.88.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The business had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. During the same period in the prior year, the company posted $1.17 EPS. The business’s revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, analysts forecast that Insulet Corporation will post 6.51 EPS for the current year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.